智翔金泰旗下两款注射液签独家协议 推进产品商业化将获付款至高超5亿元

Core Insights - Zhixiang Jintai (688443) has made substantial progress in the commercialization of its products through exclusive cooperation agreements with Xizang Kangzhe Pharmaceutical Development Co., Ltd. and RXILIENT MEDICAL PTE. LTD. for two monoclonal antibody injections [1][4] - The agreements include upfront payments and milestone payments totaling approximately 260 million yuan and 250 million yuan for the two products, with Zhixiang Jintai also set to pay promotional service fees based on sales revenue in mainland China [1][4] Company Overview - Zhixiang Jintai is an innovation-driven biopharmaceutical company focusing on autoimmune diseases, infectious diseases, and oncology, possessing full industry chain capabilities from molecular discovery to commercialization [2] - As of mid-2025, Zhixiang Jintai has 14 products under research, with two indications of its monoclonal antibody injection, Sailiqi, already approved for market, and two other injections, GR2001 and GR1801, having their New Drug Applications (NDA) accepted [2][3] Product Details - The Weikang Duta monoclonal antibody injection is a recombinant humanized monoclonal antibody targeting tetanus toxin, classified as a Class 1 therapeutic biological product, and has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [3] - The Sileweimi monoclonal antibody injection is a recombinant fully human bispecific antibody for rabies virus, also classified as a Class 1 therapeutic biological product, and is the first globally to be used for passive immunity against rabies [3] Partnership Insights - Kangzhe Pharmaceutical is focused on linking pharmaceutical innovation with commercialization, managing the entire product lifecycle, and is engaged in the development and commercialization of innovative products [4] - The cooperation agreements are effective upon signing and have an initial term of ten years after the products are approved for market in mainland China, with automatic ten-year extensions unless terminated [4] - Zhixiang Jintai aims to enhance patient accessibility and long-term development in its infectious disease pipeline through this collaboration, while continuing to build its own sales team for product promotion [4]